“differentially associated with clinically meaningful age-related outcomes, including changes to gait, balance, muscle strength, and physical function.”
Myosteatosis was not clearly linked with cardiovascular disease in humans (Liver transplant recipients; no significant difference by myosteatosis status).
“Notably, cardiovascular disease, diabetes mellitus, and malignancy did not differ significantly by myosteatosis status.”
HumansLiver transplant recipients; no significant difference by myosteatosis statusn = 503
“Myosteatosis induces proinflammatory changes that contribute to decreased muscle function, compromise mitochondrial function, and increase inflammatory response in muscles.”
Myosteatosis is linked with a higher risk of mortality in humans after TAVR (HR 3.83, 95% CI 1.54-9.53).
“Myosteatosis was associated with higher risks of both MACE (HR: 2.39, 95% CI: 1.13-5.05, P = 0.023) and all-cause mortality (HR: 3.83, 95% CI: 1.54-9.53, P = 0.004).”
Myosteatosis predicts mortality in humans (myosteatosis above 15% at T12 on CT; 12-month follow-up) (HR 3.13; 95% CI 1.01-9.70; survival 78.1% vs 96.6%).
“The presence of myosteatosis > 15% in T12-CT was an independent predictor of 12-month mortality (HR = 3.13; 95% CI: 1.01-9.70; p = 0.049)”
Humansmyosteatosis above 15% at T12 on CT; 12-month follow-upskeletal muscle12 months
Journal of renal nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation·
Myosteatosis is associated with mortality in humans.
“Myosteatosis has emerged as an important concept in muscle health as it is associated with an increased risk of adverse health outcomes, a higher rate of complications, and increased mortality”
Reviewassociated with ageing, chronic systemic and neuromuscular diseases, cancer, metabolic syndromes, degenerative events, and trauma
Myosteatosis is linked with a higher risk of major adverse cardiac events in humans after TAVR (HR 2.39, 95% CI 1.13-5.05).
“Myosteatosis was associated with higher risks of both MACE (HR: 2.39, 95% CI: 1.13-5.05, P = 0.023) and all-cause mortality (HR: 3.83, 95% CI: 1.54-9.53, P = 0.004).”
Myosteatosis predicts metabolic dysfunction-associated steatotic liver disease in humans (Post-transplant incidence in liver transplant recipients) (HR 2.25, 95% CI 1.28–3.98).
“the incidence of post-transplant metabolic dysfunction-associated steatotic liver disease (MASLD) (hazard ratio [HR] 2.25 [95% CI 1.28-3.98]; p = 0.0051)”
HumansPost-transplant incidence in liver transplant recipientsliver75.9% malesn = 503
Over a median 12.6 years, cardiovascular disease incidence was 8.7% among people with no counted scan abnormalities versus 11.3% among those without counted conventional…Over a median 12.6 years, cardiovascular disease incidence was 8.7% among people with no counted scan abnormalities versus 11.3% among those without counted conventional risk factors.
Who was studied7,531 asymptomatic participants, median 12.6 years
What changedCardiovascular disease incidence was lower: 8.7% with no counted scan abnormalities against 11.3% without counted conventional risk factors
The catchOther health differences could have contributed to the age- and sex-adjusted associations
A 5% increase in the urinary share of one substance formed from arsenic was linked to 1.62 square centimeters less abdominal muscle area.A 5% increase in the urinary share of one substance formed from arsenic was linked to 1.62 square centimeters less abdominal muscle area.